Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR3 G384D FGFR3 over exp |
| Therapy | Fexagratinib |
| Indication/Tumor Type | multiple myeloma |
| Response Type | decreased response |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR3 G384D FGFR3 over exp | multiple myeloma | decreased response | Fexagratinib | Preclinical | Actionable | In a preclinical study, multiple myeloma cells over expressing FGFR3 G384D had reduced sensitivity to Fexagratinib (AZD4547) in culture, compared to cells with ligand-independent activation of FGFR3 (PMID: 22869148). | 22869148 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (22869148) | Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance. | Full reference... |